Health Headlines: Novartis Win, Weight Loss Boosts, and More
Global health highlights include a court pausing a generic version of a heart drug, Novo Nordisk's weight loss trial success, FDA-approved cancer therapy, U.S. healthcare regulatory concerns, and Mozambique's abortion controversy impacting an AIDS program.

A U.S. appeals court has granted Novartis a temporary pause on the release of a generic version of its heart-failure drug, Entresto, as the court reviews a longer ban request. The decision holds off MSN Pharmaceuticals' launch of its product.
In Germany, authorities plan to end an emergency ordinance put in place to prevent foot-and-mouth disease, as the agriculture ministry reports stability with no new cases detected. The German agriculture minister confirmed the isolated nature of incidents.
Novo Nordisk reveals promising results from a late-stage trial of high-dose semaglutide, which achieved an impressive 20.7% weight loss in patients. The trial involved 1,407 participants, underscoring the potential of Wegovy in addressing obesity.
(With inputs from agencies.)
- READ MORE ON:
- health
- Novartis
- Entresto
- weight loss
- Novo Nordisk
- FDA
- cancer therapy
- AIDS program
- WHO
- bird flu
ALSO READ
FDA Expands Alnylam Heart Drug Approval Amid Health Policy Shifts
FDA Struggles to Meet Mandates Amidst Workforce Reductions
FDA Layoffs Disrupt Medical Device and Tobacco Product Reviews
Shakeup in Federal Health: FDA Vaccine Chief's Resignation Sparks Market Turmoil
Investor Concerns Send Novo Nordisk Shares Tumbling